A new trading day began on Tuesday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price down -9.30% from the previous day of trading, before settling in for the closing price of $33.65. CRNX’s price has ranged from $24.10 to $62.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 50.01%. Meanwhile, its annual earnings per share averaged -10.98%. With a float of $87.08 million, this company’s outstanding shares have now reached $92.93 million.
Let’s determine the extent of company efficiency that accounts for 437 employees. In terms of profitability, gross margin is -18.09%, operating margin of -32675.07%, and the pretax margin is -28720.69%.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 6.99%, while institutional ownership is 103.91%. The most recent insider transaction that took place on Mar 19 ’25, was worth 86,021. In this transaction Chief Med and Dev Officer of this company sold 2,515 shares at a rate of $34.20, taking the stock ownership to the 72,233 shares. Before that another transaction happened on Mar 19 ’25, when Company’s Chief Operating Officer sold 7,162 for $34.20, making the entire transaction worth $244,964. This insider now owns 87,491 shares in total.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -10.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.49% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 23.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.70, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -4.38 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Looking closely at Crinetics Pharmaceuticals Inc (NASDAQ: CRNX), its last 5-days average volume was 0.83 million, which is a drop from its year-to-date volume of 1.03 million. As of the previous 9 days, the stock’s Stochastic %D was 48.98%. Additionally, its Average True Range was 1.71.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 17.72%, which indicates a significant decrease from 29.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.56% in the past 14 days, which was lower than the 62.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $32.43, while its 200-day Moving Average is $46.20. However, in the short run, Crinetics Pharmaceuticals Inc’s stock first resistance to watch stands at $32.50. Second resistance stands at $34.48. The third major resistance level sits at $35.53. If the price goes on to break the first support level at $29.47, it is likely to go to the next support level at $28.41. Now, if the price goes above the second support level, the third support stands at $26.43.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
With a market capitalization of 2.86 billion, the company has a total of 93,629K Shares Outstanding. Currently, annual sales are 1,040 K while annual income is -298,410 K. The company’s previous quarter sales were 0 K while its latest quarter income was -76,830 K.
